| ¿µ¹® | carcinoembryonic antigen | ÇÑ±Û | ¾Ï¹è¾ÆÇ׿ø |
|---|---|---|---|
| ¼³¸í | ¿ø·¡ žÆÀÇ ÀåÁ¶Á÷¿¡¼ Á¤»óÀûÀ¸·Î Á¸ÀçÇÏ´Â ¹°Áú·Î žƱâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ ÀÖ´Â °æ¿ì¿¡ ¼ºÀο¡¼µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù. |
||
| ¿µ¹® | antigen | ÇÑ±Û | Ç׿ø |
|---|---|---|---|
| ¼³¸í | ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀÎ ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼ ƯÀÌÇÏ°Ô ¹ÝÀÀÇÒ ¼ö ÀÖ´Â ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù. |
||
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| AA | abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];... |
| BLP | Bombesin-like peptides |
|---|---|
| CTAP | Connective Tissue Activating Peptides |
| GHRP | Growth hormone releasing peptides |
| MPs | Muramyl peptides |
| SP | Signal peptides |
| amino acids, peptides, and proteins | Amino acids and chains of amino acids connected by peptide linkages. (12 Dec 1998) |
|---|---|
| bitter peptides | Peptides that have a bitter taste and may spoil certain foods; often contain high proportions of leucyl, valyl, and aromatic amino acid residues. (05 Mar 2000) |
| peptides | Any member of a class of compounds of low molecular weight which yield two or more amino acids on hydrolysis. Formed by loss of water from the nh2 and cooh groups of adjacent amino acids, they are known as di-, tri-, tetra- (etc.) peptides, depending on the number of amino acids in the molecule. Peptides form the constituent parts of proteins. (12 Dec 1998) |
| signal peptides | Additional polypeptide sequence of 25 to 30 residues at the amino-terminal or carboxy-terminal end of proteins. The signal sequence signals the cellular fate or destination of a newly synthesised protein directing it to its ultimate destination in the cell. These leaders are recognised by the signal recognition particle and bound by specific receptor sites on the outer surface of the endoplasmic reticulum. They are then transported into the cisterna of the endoplasmic reticulum and from there directed to their ultimate destination in the cell. In prokaryotes, the signal peptides attach to the plasma membrane. These signal sequences are ultimately removed by specific peptidases. (12 Dec 1998) |
| opioid peptides | The endogenous peptides with opiate-like activity. The three major classes currently recognised are the enkephalins, the dynorphins, and the endorphins. Each of these families derives from different precursors, proenkephalin, prodynorphin, and pro-opiomelanocortin, respectively. There are also at least three classes of opioid receptors, but the peptide families do not map to the receptors in a simple way. (12 Dec 1998) |
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| antigen p150,95 | A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|